Holy Crap! Why is a Cardiologist Speaking at a GI Meeting? Jonathan A. Rapp, MD, FACC, FSCAI Cardiologist, Mercy Heart Institute Cincinnati, OH

Similar documents
Bleeding Management Strategies. Aiming for the best Outcomes August 27, Amit Gupta, MD FACC FSCAI Interventional Cardiologist CANM

Anticoagulation Management Around Endoscopy: GI Perspective. Nathan Landesman, DO FACOI Flint Gastroenterology Associates October 11, 2017

HEART OF THE MATTER: cardiac issues in safe endoscopy & sedation

Asif Serajian DO FACC FSCAI

Antiplatelet and Anti-Thrombotic Therapy. Ivan Anderson, MD RIHVH Cardiology

Antiplatelets and Anticoagulants. Helen Leung, PharmD PGY1 Pharmacy Resident Memorial Hermann-Texas Medical Center

Prostate Biopsy Alerts

3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.

Update in Perioperative Anticoagulation and Antiplatelet management

Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017

Clinical Practice Guideline for Anticoagulation Management

CARDIOLOGY. Certification Updates with Clinical Aspects. Federal Aviation Administration

OUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME. TARGET AUDIENCE: All Canadian health care professionals.

Dual antiplatelet therapy (DAPT) in the era of Novel Oral Anticoagulants (NOACs) SACIS 2015

Xarelto (rivaroxaban)

Pradaxa (dabigatran)

Alberta Colorectal Cancer Screening Program (ACRCSP) Antithrombotic Management

Cardiac Perioperative Risk Assessment American Heart Association Guidelines

Acute Coronary Syndromes

2010, Metzler Helfried

Disclosures No Conflicts of Interest Final syllabus available by

Eliquis and plavix combination therapy

Challenging Anticoagulation Case Studies. Earl J. Hope, M.D. Tower Health Cardiology

Disclosures. Updates in Interventional Cardiology and Guidelines 6/12/2017. No Conflicts of Interest

Nanik Hatsakorzian Pharm.D/MPH

Disclosures. Overview. Have you ever. The Perioperative Management of Anticoagulants. No financial conflicts of interest to disclose

Disclosures. Interventional Cardiology for the Non-Cardiologist: New Innovations and New Guidelines 10/13/17. No Conflicts of Interest

Peri-Procedural Management of Antithrombotic Agents

Perioperative Cardiovascular Evaluation and Care for Noncardiac. Dr Mahmoud Ebrahimi Interventional cardiologist 91/9/30

on Anti-coagulants -- Is It Safe? And When to Stop?

Dual Antiplatelet Therapy Made Practical

Clinical Policy: Dalteparin (Fragmin) Reference Number: ERX.SPA.207 Effective Date:

North Wales Cardiac Network Guidelines on oral antiplatelet therapy in cardiovascular disease

FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS

Disclosure Slide. Controversies in Anticoagulation. Presenter Disclosure Information. Challenges in Anticoagulation

INR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA

Afib, Stroke, and DOAC. Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS

Preoperative Evaluation Guidelines and Work up

2017 Bryan Health Primary Care Conference. Dale Hansen MD Bryan Heart 5/20/17

Adult Reversal of Anticoagulation and Anti-platelet Agents for Life- Threatening Bleeding or Emergency Surgery Protocol

Cardiac evaluation for the noncardiac. Nathaen Weitzel MD University of Colorado Denver Dept of Anesthesiology

ACCP Cardiology PRN Journal Club

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

DISCLOSURE. What I am Talking About. Rational Use of Antiplatelet Agents. Aspirin. Tom DeLoughery, MD MACP FAWM

Timing of Surgery After Percutaneous Coronary Intervention

Controversies in Perioperative Medicine

Guiding Secondary Stroke Prevention through Evaluation of Ischemic Stroke Etiology

Controversies in Cardiac Pharmacology

What s new in Cardiovascular medicine? Dr Stephen Dorman Consultant Cardiologist, Morriston Cardiac Centre Mid & West Cardiac Network Lead

Complicated issues in GI bleeding for internists? Nonthalee Pausawasdi, M.D. Faculty of Medicine Siriraj Hospital

When and how to combine antiplatelet agents and anticoagulant?

I have no disclosures

Dr Calum Young Cardiologist Tauranga

Anticoagulants and antiplatelet therapy in the older patient: Choosing wisely

Management of Atrial Fibrillation in the Hospitalized Patient

The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center

a. A pharmacist may order a baseline SCr per protocol

Clinical Controversies in Perioperative Medicine

Disclosures. Theodore A. Bass MD, FSCAI. The following relationships exist related to this presentation. None

Update on the NOAC s: 2018 Daniel Blanchard, MD, FACC, FAHA

Direct Oral Anticoagulants An Update

Endoscopy and the Anticoagulated Patient

Clinicians and Facilities: RESOURCES WHEN CARING FOR WOMEN WITH ADULT CONGENITAL HEART DISEASE OR OTHER FORMS OF CARDIOVASCULAR DISEASE!!

Preventing Stroke in Patients with Atrial Fibrillation: USING THE EVIDENCE

Indications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014

Update on Oral Anticoagulation for Mechanical Heart Valves

Learning Objectives. Epidemiology of Acute Coronary Syndrome

Treatment with Apixaban Eliquis

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

DAPT in CAD, Acute & Chronic CAD, antiplatelet therapy non-responders

Who uses these medications? Assessing Patients Who Take Blood-Altering Medications. 3 Types of Acute Coronary Syndromes. Platelet-Related Fatalities

Index. Note: Page numbers of article titles are in boldface type.

Manuel Castella MD PhD Hospital Clínic, University of

Scope of the Problem: DAPT and Triple Therapy after Stenting

REBEL. Platinum Chromium Coronary Stent System. Patient Information Guide

Triple Therapy: A review of the evidence in acute coronary syndrome. Stephanie Kling, PharmD, BCPS Sanford Health

Performance and Quality Measures 1. NQF Measure Number. Coronary Artery Disease Measure Set

Oral anti-thrombotic therapy-management in patients requiring endoscopy

EAU GUIDELINES ON THROMBOPROPHYLAXIS IN UROLOGICAL SURGERY

Perioperative Anticoagulation Management

Preoperative Management of Patients Receiving Antithrombotics

Let s Gi e The So ethi g To Clot About: Controversies in Anticoagulation

PCI in Patients with AF Optimizing Oral Anticoagulation Regimen

Make you feel better Make you live longer

TAVI and Valve Replacement Thromboprophylaxis. Warren Prokopiw Pharmacy Resident

The Future of Oral Antiplatelets in PAD and CAD Christopher Paris, MD, FACC, FSCAI

Recommended Evaluation Data Excerpt from NVIC 04-08

Perioperative Management. Perioperative Management of Cardiovascular Medications

New Antithrombotic and Antiplatelet Drugs in CAD : (Factor Xa inhibitors, Direct Thrombin inhibitors and Prasugrel)

Cindy Stephens, MSN, ANP Kelly Walker, MS, ACNP Peter Cohn, MD, FACC

Heart Valves: Before and after surgery

Preoperative Evaluation: Patients with Cardiac Disease

Clinical Practice Committee Anticoagulation Bridging Document

ANTITHROMBOTIC THERAPY 2010 Antitrombotik tedavi alan hastalarda operasyon hazırlığı

Should We Reconsider using Anticoagulation for Biological Tissue Valves

NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS

Program Metrics. New Unique ID. Old Unique ID. Metric Set Metric Name Description. Old Metric Name

Guidelines for the Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults

t. Recommendations for periprocedural anticoagulation are available lhrough the American College of Chest Physicians Clinical Practice Guidelines.

Disclosures. Updates in Acute Coronary Syndromes 10/21/17. No Conflicts of Interest. Updates in Acute Coronary Syndromes. Krishan Soni, MD, MBA, FACC

Transcription:

Holy Crap! Why is a Cardiologist Speaking at a GI Meeting? Jonathan A. Rapp, MD, FACC, FSCAI Cardiologist, Mercy Heart Institute Cincinnati, OH

Goals and Objectives Discuss cardiac considerations for patients undergoing endoscopic procedures Patients with coronary artery disease Oral anticoagulation and artifical heart valves Congestive heart failure Endocarditis prophylaxis Pacemakers and ICDs Questions and Answers

Coronary Artery Disease: Antiplatelet Therapy What medications constitute antiplatelet therapy? Aspirin Clopidogrel (Plavix) Prasugrel (Effient) Ticagrelor (Brilinta)

Coronary Artery Disease: Antiplatelet Therapy WHY is your patient on antiplatelet therapy? Chronic therapy or recent problem? Stent or no stent?

Recent Stent? Drug-Eluting Stents Examples: Xience, Promus, Endeavor, Taxus Stents are coated with a drug that is slowly released into the artery that delays restenosis The drug also delays endothelialization and healing Requires ONE YEAR of dual antiplatelt therapy Bare-Metal Stents Examples: Vision, Integrity, Driver No drug on the stent Endothelialization and healing occur within a month Requires ONE MONTH of dual antiplatelt therapy (unless stent was for ACS-->then one year preferred). Kushner et al. Circulation 2009; 120: 2271-2306

Stent Thrombosis 64% rate of death or MI 8.9% six-month mortality Unless there is an emergency (hemorrhage), do NOT STOP antiplatelet therapy in patients recently stented without a cardiology consult Cutlip et al. Stent thrombosis in the modern era. Circulation 2001; 103: 1967-1971

Stent Thrombosis Referred by: Confirmed By: ER MD I avr V1 V4 II avl V2 V5 III avf V3 V6 II II V5

Antiplatelet Agents in CAD Patients Emergency? Do what you need to do Old coronary stent (>1 year for DES, >30 days for BMS)? Continue aspirin at 81 mg daily No stent? Aspirin 81 mg if possible. On aspirin and plavix/effient/ticagrelor? WHY? Recent MI: Continue both meds and delay procedure if possible (or perform without stopping medications)

Antiplatelet Agents in CAD Patients Recent stent: Refer to guidelines above What s the risk of stent thrombosis if stopping aspirin and plavix/effient? We don t know. Unethical to study that but everyone has seen it! NEVER WRONG TO CALL A CARDIOLOGIST

When to Stop Antiplatelet Drugs Aspirin: Should be OK to use 81 mg Clopidogrel (Plavix): 5 days Prasugrel (Effient): 7 days Ticagrelor (Brilinta): 5 days

Pre-Operative Clearance Step 1 Emergency? Operating Room Step 2 No Active Cardiac Condition? Yes Evaluate, treat Consider Operating Step 3 No Low risk procedure? Yes Proceed with procedure Step 4 Endoscopic procedures are low risk Step 5

Active Cardiac Conditions Condition Unstable Coronary Syndromes Unstable Arrhythmias Decompensated Heart Failure Severe Valvular Disease Example Unstable Angina, Recent MI Mobitz Type II Block (or worse), SVT, Symptomatic bradycardia, VT NYHA Class 4 CHF, Worsening CHF Severe AS, symptomatic MS

Anticoagulation: Which Cardiac Conditions Require It? Atrial Fibrillation (risk of stroke ~6-7%/ year; 0.016% per day) DVT/PE Artificial heart valve Recent large anterior MI No good data but we do it anyway

Anticoagulation Warfarin Direct Thrombin Inhibitors Anti Xa

Other Anticoagulants Warfarin (Coumadin) Vitamin K antagonist Dabigatran (Pradaxa) Direct thrombin inhibitor Riveroxaban (Xarelto), Apixaban (Eliquis) Factor Xa inhibitor

Oral Anticoagulants Class When to Stop Reversal Agent Warfarin Direct Thrombin Inhibitors Factor Xa Inhibitors 5 Days Prior 48 Hours Drug-Free 24 Hours Vitamin K, FFP NONE NONE

Problem Strategy Atrial Fibrillation? Stop anticoagulation, resume after DVT/PE Stop anticoagulation, BRIDGE before and after procedure Bridging: Anticoagulate with drugs with shorter half-life than the oral drug which gives the full effect while oral drug wears off.

Heart Valves and Anticoagulation Table 37. Recommendations for Antithrombotic Therapy in Patients With Prosthetic Heart Valves Aspirin (75 100 mg) Warfarin (INR 2.0 3.0) Warfarin (INR 2.5 3.5) No Warfarin Mechanical prosthetic valves AVR low risk Less than 3 months Class I Class I Class IIa Greater than 3 months Class I Class I AVR high risk Class I Class I MVR Class I Class I Biological prosthetic valves AVR low risk Less than 3 months Class I Class IIa Class IIb Greater than 3 months Class I Class IIa AVR high risk Class I Class I MVR low risk Less than 3 months Class I Class IIa Greater than 3 months Class I Class IIa MVR high risk Class I Class I Depending on patients clinical status, antithrombotic therapy must be individualized (see special situations in text). In patients receiving warfarin, aspirin is recommended in virtually all Everyone gets a baby aspirin (indefinitely) Bonow et al. ACC/AHA 2006 Guidelines for the Management of Patients with Valvular Heart Disease.

Bioprosthetic Valves Valves made from bovine or porcine tissue < 3 months after surgery > 3 months after surgery Coumadin No coumadin If a procedure is needed and the patient is in the coumadin window, bridge with IV heparin if possible

Mechanical Heart Valves Mechanical Heart Valve Stop anticoagulation, bridge before and after procedure Thrombosis

Anticoagulation Strategy for Mechanical Valves High Risk of Thrombosis (any mitral, older aortic): Stop coumadin for 2-3 days, bridge with heparin after INR < 2 Low Risk of Thrombosis (aortic bileaflet): Stop coumadin for 2-3 days, NO bridge with heparin unless other risk factors present AFTER procedure, start heparin and warfarin, and administer heparin until INR at goal What about lovenox? Probably OK but not studied so heparin is recommended

Congestive Heart Failure NYHA Class Description I II III IV No symptoms Slight limitation of activity; activity causes mild symptoms Comfortable at rest, minor activity causes significant symptoms Symptoms at rest, severely limited physical activity

CHF Considerations Blood pressure may already be low (BB, ACE-i, low C.O., etc.) Be careful with sedation Be careful with sedation Be careful with sedation Oxygenation may already be low If you have a problem, they may be harder to get back They may be very sensitive to IV fluids and can be tipped over easily

Endocarditis Prophylaxis Controversial topic There are AHA/ACC guidelines; some people just don t follow them We probably don t need it as much as we use it Endocarditis is life-threatening and possibly disastrous, so we probably over-treat

Endocarditis Organ infarction Mycotic aneurysm CHF MI Death

Prophylaxis is Recommended for: Prosthetic valves or prosthetic material used for valve repair Previous endocarditis Congenital heart disease Cardiac transplant Administration of antibiotics solely to prevent endocarditis is not recommended for patients who undergo a GU or GI tract procedure. Nishimura et al. ACC/AHA 2008 Guideline Update on Valvular Heart Disease: Focussed Update on Infective Endocarditis

Pacemakers and Implantable Cardioverter-Defibrillators (ICDs) Get a good history Is the device a packemaker or ICD (all ICDs have pacing functions) Why do you have it? Heart failure, prior sudden cardiac death What brand is it?

Adjust Settings If electro-cautery is used during a procedure, the device may interpret the electricity as ventricular fibrillation and give an inappropriate discharge If the patient is pacemaker dependent, the device may think it hears electricity from the heart when it is really sensing electrocautery

Magnet Pacemaker: Usually places in asynchronous mode Different for each device Pacemaker will discharge at steady rate regardless of what it hears from the heart ICD: Disables ICD function (does not necessarily alter pacing function)

Summary Cardiac problems can complicate the treatment of GI problems If there is an immediate threat to life, do what you have to do Unless there is an immediate threat to life, do NOT stop antiplatelet medications or antithrombotic agents without a thorough history or, better yet, a cardiology consult. Transfusing 1-2 units of blood beats death or MI Thombosed heart valves are disastrous

Summary Only the most unstable patients are truly at risk for cardiac events from GI procedures CHF patients require special attention in the endoscopy lab ACC/AHA Guidelines do NOT endorse endocarditis prophylaxis anymore (but we do it anway) Pacemakers and ICDs should be appropriately adjusted before procedures

Thank You